|
WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US20150166984A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting alpha-antitrypsin point mutations
|
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
CN116064401A
(zh)
*
|
2015-07-29 |
2023-05-05 |
昂克医疗有限公司 |
具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系
|
|
US10906951B2
(en)
*
|
2015-07-29 |
2021-02-02 |
Onk Therapeutics Limited |
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
|
|
GB2557123B
(en)
*
|
2015-07-31 |
2021-11-03 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
SG10202104041PA
(en)
|
2015-10-23 |
2021-06-29 |
Harvard College |
Nucleobase editors and uses thereof
|
|
EP3373941A4
(en)
*
|
2015-11-09 |
2019-03-27 |
Aperisys, Inc. |
MODIFIED IMMUNOCELLS AND USES THEREOF
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
WO2017214569A1
(en)
*
|
2016-06-09 |
2017-12-14 |
Regents Of The University Of Minnesota |
Genome-edited nk cell and methods of making and using
|
|
JP7195154B2
(ja)
*
|
2016-07-06 |
2022-12-23 |
セレクティス |
初代免疫細胞における逐次遺伝子編集
|
|
KR20250103795A
(ko)
|
2016-08-03 |
2025-07-07 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US10724043B2
(en)
|
2016-10-06 |
2020-07-28 |
Nantbio, Inc. |
Multi-pulse transfection methods and cells
|
|
SG11201903089RA
(en)
|
2016-10-14 |
2019-05-30 |
Harvard College |
Aav delivery of nucleobase editors
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
CA3048979A1
(en)
*
|
2016-12-30 |
2018-07-05 |
Celularity Inc. |
Genetically modified natural killer cells
|
|
CA3052473A1
(en)
*
|
2017-02-09 |
2018-08-16 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and compositions and methods thereof
|
|
WO2018152340A1
(en)
*
|
2017-02-15 |
2018-08-23 |
The Regents Of The University Of California |
Compositions and methods for activating nk cells
|
|
EP3592381A1
(en)
*
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Cancer vaccine
|
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
WO2018165629A1
(en)
|
2017-03-10 |
2018-09-13 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
|
WO2018176009A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
JP2020516654A
(ja)
*
|
2017-04-13 |
2020-06-11 |
センティ バイオサイエンシズ インコーポレイテッド |
組み合わせがん免疫療法
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
EP3630962A4
(en)
*
|
2017-05-25 |
2021-01-20 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
|
PE20241587A1
(es)
|
2017-06-02 |
2024-08-01 |
Pfizer |
Receptores de antigenos quimericos que se dirigen a flt3
|
|
EP3638260A1
(en)
*
|
2017-07-21 |
2020-04-22 |
Cellectis |
Engineered immune cells resistant to tumor microoenvironment
|
|
WO2019016360A1
(en)
*
|
2017-07-21 |
2019-01-24 |
Cellectis |
MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
|
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
|
EP3441461A1
(en)
*
|
2017-08-11 |
2019-02-13 |
Baylor College of Medicine |
Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
US11795443B2
(en)
|
2017-10-16 |
2023-10-24 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
|
CA3079076A1
(en)
*
|
2017-10-18 |
2019-04-25 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Methods and compounds for improved immune cell therapy
|
|
EP3707258A1
(en)
*
|
2017-11-06 |
2020-09-16 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy
|
|
WO2019118949A1
(en)
|
2017-12-15 |
2019-06-20 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
WO2019165121A1
(en)
|
2018-02-21 |
2019-08-29 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses therof
|
|
KR20200130826A
(ko)
*
|
2018-03-15 |
2020-11-20 |
케이에스큐 세러퓨틱스 인코포레이티드 |
개선된 면역요법을 위한 유전자-조절 조성물 및 방법
|
|
CA3100341A1
(en)
*
|
2018-05-16 |
2019-11-21 |
Research Institute Of Nationwide Children's Hospital |
Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
DK3806903T5
(da)
|
2018-06-14 |
2024-08-19 |
2Seventy Bio Inc |
Cd79a kimæriske antigenreceptorer
|
|
EP3820495A4
(en)
|
2018-07-09 |
2022-07-20 |
The Broad Institute Inc. |
RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
|
|
WO2020072059A1
(en)
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
US12410402B2
(en)
|
2018-11-21 |
2025-09-09 |
Indapta Therapeutics, Inc. |
Methods for expansion of natural killer (NK) cell subset and related compositions and methods
|
|
AU2019386140A1
(en)
|
2018-11-28 |
2021-06-24 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
JP2022518463A
(ja)
*
|
2019-01-16 |
2022-03-15 |
ビーム セラピューティクス インク． |
抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
SG11202108346WA
(en)
|
2019-02-13 |
2021-08-30 |
Beam Therapeutics Inc |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
EP3924467A1
(en)
*
|
2019-02-15 |
2021-12-22 |
Editas Medicine, Inc. |
Modified natural killer (nk) cells for immunotherapy
|
|
EP3942043A2
(en)
|
2019-03-19 |
2022-01-26 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
|
RU2731293C1
(ru)
*
|
2019-04-12 |
2020-09-01 |
Игорь Петрович Белецкий |
Способ получения генно-модифицированных линий клеток натуральных киллеров с нокаутированным геном PD-1 и повышенной экспрессией белков семейства Фактора Некроза Опухолей для иммунотерапии онкологических заболеваний
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
CN115279398B
(zh)
|
2019-09-27 |
2025-07-04 |
比姆医疗股份有限公司 |
治疗液态癌症的组合物和方法
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
JP2022554284A
(ja)
*
|
2019-10-31 |
2022-12-28 |
リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル |
Ｃｄ３８ノックアウト初代および増殖ヒトｎｋ細胞の生成
|
|
BR112022022603A2
(pt)
|
2020-05-08 |
2023-01-17 |
Broad Inst Inc |
Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
|
|
US12576151B2
(en)
|
2020-09-25 |
2026-03-17 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
US20230416786A1
(en)
|
2020-11-30 |
2023-12-28 |
Cellectis Sa |
Use of aminoquinoline compounds for higher gene integration
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
AU2021392809A1
(en)
*
|
2020-12-03 |
2023-07-20 |
Nkarta, Inc. |
Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy
|
|
TW202237827A
(zh)
|
2020-12-03 |
2022-10-01 |
美商世紀治療股份有限公司 |
經基因工程改造之細胞及其用途
|
|
US20240299542A1
(en)
*
|
2021-01-05 |
2024-09-12 |
City Of Hope |
Natural killer cells engineered to reduce or eliminate cbl-b and uses thereof
|
|
IL311570A
(en)
|
2021-10-14 |
2024-05-01 |
Arsenal Biosciences Inc |
Immune cells with common expression chain and logic gate systems
|
|
US20250041338A1
(en)
*
|
2021-11-17 |
2025-02-06 |
The Regents Of The University Of California |
Gene targets for t-cell-based immunotherapy to overcome suppressive factors
|
|
TW202342737A
(zh)
*
|
2022-02-07 |
2023-11-01 |
中國大陸商杭州啟函生物科技有限公司 |
增強免疫療法的系統和方法
|
|
WO2024073010A1
(en)
*
|
2022-09-28 |
2024-04-04 |
University Of Cincinnati |
Inhibition of natural killer cell cytoxocity
|
|
WO2024124242A2
(en)
*
|
2022-12-09 |
2024-06-13 |
Research Institute At Nationwide Children's Hospital |
Combination cd38ko/car ki nk cell immunotherapy for dual targeting with cd38 monoclonal antibodies
|
|
JP2026507228A
(ja)
|
2023-03-03 |
2026-02-27 |
アーセナル バイオサイエンシズ インコーポレイテッド |
Ｐｓｍａ及びｃａ９を標的とするシステム
|
|
FI131854B1
(en)
|
2023-05-29 |
2026-01-12 |
Onni Biotechnologies Oy |
Modified natural killer cells with enhanced cytotoxic activity and greater survival
|
|
CN117430721B
(zh)
*
|
2023-10-25 |
2024-06-25 |
北京景达生物科技有限公司 |
Cd123靶向car-nk细胞的制备及其应用
|